NASDAQ: OBIOOrchestra Biomed Holdings Inc Stock
$3.99+0.12 (+3.1%)
Updated Jun 18, 2026
OBIO Price
$3.99
Fair Value Price
N/A
Market Cap
$238.92M
52 Week Low
$2.20
52 Week High
$5.42
P/E
-4.11x
P/B
5.8x
P/S
8.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$32.72M
Earnings
-$54.64M
Gross Margin
99.5%
Operating Margin
-160.44%
Profit Margin
-167.6%
Debt to Equity
1.21
Operating Cash Flow
-$55M
Beta
0.95
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
OBIO Overview
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OBIO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OBIO
Ranked#291 of 465
Ranked#291 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important OBIO news, forecast changes, insider trades & much more!
OBIO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OBIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OBIO is poor value based on its book value relative to its share price (5.8x), compared to the US Biotechnology industry average (4.95x)
P/B vs Industry Valuation
OBIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OBIO due diligence checks available for Premium users.
Valuation
OBIO fair value
Fair Value of OBIO stock based on Discounted Cash Flow (DCF)
Price
$3.99
Fair Value
-$0.01
Undervalued by
52,811.93%
OBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.11x
Industry
15.77x
Market
9.47x
OBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.8x
Industry
4.95x
OBIO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OBIO's financial health
Profit margin
Revenue
$110.0k
Net Income
-$20.7M
Profit Margin
-18,778.2%
OBIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OBIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$100.7M
Liabilities
$49.7M
Debt to equity
1.21
OBIO's short-term assets ($96.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OBIO's short-term assets ($96.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OBIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.2M
Investing
$10.3M
Financing
$5.5M
OBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OBIO vs Biotech Stocks
Orchestra Biomed Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.